Tyrosine kinase domain mutations in chronic myelogenous leukemia patients: A single center experience

INTRODUCTION: Despite the impressive responses achieved with tyrosine kinase inhibitor (TKI) therapy, treatment resistance develops in 16–33% of patients of chronic myelogenous leukemia (CML). Of the BCR-ABL1 dependent mechanisms, mutations in the tyrosine kinase domain (TKD) are the commonest cause...

Descripción completa

Detalles Bibliográficos
Autores principales: Bommannan, KB, Naseem, S, Binota, J, Varma, N, Malhotra, P, Varma, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196293/
https://www.ncbi.nlm.nih.gov/pubmed/34747876
http://dx.doi.org/10.4103/jpgm.JPGM_781_20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196293/
https://www.ncbi.nlm.nih.gov/pubmed/34747876
http://dx.doi.org/10.4103/jpgm.JPGM_781_20

Ejemplares similares